Cargando…

Overcoming the UCB HSCs –Derived NK cells Dysfunction through Harnessing RAS/MAPK, IGF-1R and TGF-β Signaling Pathways

BACKGROUND: The natural killer (NK) cells differentiated from umbilical cord blood (UCB) hematopoietic stem cells (HSCs) may be more suitable for cell-based immunotherapy compared to the NK cells from adult donors. This is due to the possibility to choose alloreactive donors and potentially more rob...

Descripción completa

Detalles Bibliográficos
Autores principales: Shokouhifar, Alireza, Anani Sarab, Gholamreza, Yazdanifar, Mahboubeh, Fereidouni, Mohammad, Nouri, Masoumeh, Ebrahimi, Marzieh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185927/
https://www.ncbi.nlm.nih.gov/pubmed/34098947
http://dx.doi.org/10.1186/s12935-021-01983-z
_version_ 1783704857121652736
author Shokouhifar, Alireza
Anani Sarab, Gholamreza
Yazdanifar, Mahboubeh
Fereidouni, Mohammad
Nouri, Masoumeh
Ebrahimi, Marzieh
author_facet Shokouhifar, Alireza
Anani Sarab, Gholamreza
Yazdanifar, Mahboubeh
Fereidouni, Mohammad
Nouri, Masoumeh
Ebrahimi, Marzieh
author_sort Shokouhifar, Alireza
collection PubMed
description BACKGROUND: The natural killer (NK) cells differentiated from umbilical cord blood (UCB) hematopoietic stem cells (HSCs) may be more suitable for cell-based immunotherapy compared to the NK cells from adult donors. This is due to the possibility to choose alloreactive donors and potentially more robust in vivo expansion. However, the cytotoxicity of UCB-HSC-derived NK cells against cancer cells might be suboptimal. To overcome this obstacle, we attempted to generate NK cells with potent antitumor activity by targeting RAS/MAPK, IGF-1R and TGF-β signaling pathways using IL-15, IGF-1 and SIS3 respectively. METHODS: The CD34 + cells were isolated from human UCB mononuclear cells through magnetic activation cell sorting (MACS) with purity of (≥ 90%) and were subjected to differentiate into NK cells. After 21 days of induction with SFTG36 (SCF, FLt-3L, TPO, GM-CSF, IL-3 and IL-6), IS721 (IGF-1, SIS3, IL-7 and IL-21) and IL-15/Hsp70 media, NK cells phenotypes were studied and their cytotoxicity against K562 human erythroleukemia cells and SKOV3 ovarian carcinoma cells was analyzed. RESULTS: The NK cells induced in SFTG36/IS721 medium were selected for activation due to their higher expression of CD56 + 16 + CD3 −  (93.23% ± 0.75) and mean fluorescence intensity (MFI) of NKG2D + (168.66 ± 20.00) and also a higher fold expansion potential (11.893 ± 1.712) compared to the other groups. These cells once activated with IL-15, demonstrated a higher cytotoxicity against K562 (≥ 90%; P ≤ 0.001) and SKOV3 tumor cells (≥ 65%; P ≤ 0.001) compared to IL-15/Hsp70-activated NK cells. CONCLUSIONS: The differentiation of ex vivo expanded CD34 + cells through manipulation of RAS/MAPK, IGF-1R and TGF-β signaling pathways is an efficient approach for generating functional NK cells that can be used for cancer immunotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-021-01983-z.
format Online
Article
Text
id pubmed-8185927
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81859272021-06-09 Overcoming the UCB HSCs –Derived NK cells Dysfunction through Harnessing RAS/MAPK, IGF-1R and TGF-β Signaling Pathways Shokouhifar, Alireza Anani Sarab, Gholamreza Yazdanifar, Mahboubeh Fereidouni, Mohammad Nouri, Masoumeh Ebrahimi, Marzieh Cancer Cell Int Primary Research BACKGROUND: The natural killer (NK) cells differentiated from umbilical cord blood (UCB) hematopoietic stem cells (HSCs) may be more suitable for cell-based immunotherapy compared to the NK cells from adult donors. This is due to the possibility to choose alloreactive donors and potentially more robust in vivo expansion. However, the cytotoxicity of UCB-HSC-derived NK cells against cancer cells might be suboptimal. To overcome this obstacle, we attempted to generate NK cells with potent antitumor activity by targeting RAS/MAPK, IGF-1R and TGF-β signaling pathways using IL-15, IGF-1 and SIS3 respectively. METHODS: The CD34 + cells were isolated from human UCB mononuclear cells through magnetic activation cell sorting (MACS) with purity of (≥ 90%) and were subjected to differentiate into NK cells. After 21 days of induction with SFTG36 (SCF, FLt-3L, TPO, GM-CSF, IL-3 and IL-6), IS721 (IGF-1, SIS3, IL-7 and IL-21) and IL-15/Hsp70 media, NK cells phenotypes were studied and their cytotoxicity against K562 human erythroleukemia cells and SKOV3 ovarian carcinoma cells was analyzed. RESULTS: The NK cells induced in SFTG36/IS721 medium were selected for activation due to their higher expression of CD56 + 16 + CD3 −  (93.23% ± 0.75) and mean fluorescence intensity (MFI) of NKG2D + (168.66 ± 20.00) and also a higher fold expansion potential (11.893 ± 1.712) compared to the other groups. These cells once activated with IL-15, demonstrated a higher cytotoxicity against K562 (≥ 90%; P ≤ 0.001) and SKOV3 tumor cells (≥ 65%; P ≤ 0.001) compared to IL-15/Hsp70-activated NK cells. CONCLUSIONS: The differentiation of ex vivo expanded CD34 + cells through manipulation of RAS/MAPK, IGF-1R and TGF-β signaling pathways is an efficient approach for generating functional NK cells that can be used for cancer immunotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-021-01983-z. BioMed Central 2021-06-07 /pmc/articles/PMC8185927/ /pubmed/34098947 http://dx.doi.org/10.1186/s12935-021-01983-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Primary Research
Shokouhifar, Alireza
Anani Sarab, Gholamreza
Yazdanifar, Mahboubeh
Fereidouni, Mohammad
Nouri, Masoumeh
Ebrahimi, Marzieh
Overcoming the UCB HSCs –Derived NK cells Dysfunction through Harnessing RAS/MAPK, IGF-1R and TGF-β Signaling Pathways
title Overcoming the UCB HSCs –Derived NK cells Dysfunction through Harnessing RAS/MAPK, IGF-1R and TGF-β Signaling Pathways
title_full Overcoming the UCB HSCs –Derived NK cells Dysfunction through Harnessing RAS/MAPK, IGF-1R and TGF-β Signaling Pathways
title_fullStr Overcoming the UCB HSCs –Derived NK cells Dysfunction through Harnessing RAS/MAPK, IGF-1R and TGF-β Signaling Pathways
title_full_unstemmed Overcoming the UCB HSCs –Derived NK cells Dysfunction through Harnessing RAS/MAPK, IGF-1R and TGF-β Signaling Pathways
title_short Overcoming the UCB HSCs –Derived NK cells Dysfunction through Harnessing RAS/MAPK, IGF-1R and TGF-β Signaling Pathways
title_sort overcoming the ucb hscs –derived nk cells dysfunction through harnessing ras/mapk, igf-1r and tgf-β signaling pathways
topic Primary Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185927/
https://www.ncbi.nlm.nih.gov/pubmed/34098947
http://dx.doi.org/10.1186/s12935-021-01983-z
work_keys_str_mv AT shokouhifaralireza overcomingtheucbhscsderivednkcellsdysfunctionthroughharnessingrasmapkigf1randtgfbsignalingpathways
AT ananisarabgholamreza overcomingtheucbhscsderivednkcellsdysfunctionthroughharnessingrasmapkigf1randtgfbsignalingpathways
AT yazdanifarmahboubeh overcomingtheucbhscsderivednkcellsdysfunctionthroughharnessingrasmapkigf1randtgfbsignalingpathways
AT fereidounimohammad overcomingtheucbhscsderivednkcellsdysfunctionthroughharnessingrasmapkigf1randtgfbsignalingpathways
AT nourimasoumeh overcomingtheucbhscsderivednkcellsdysfunctionthroughharnessingrasmapkigf1randtgfbsignalingpathways
AT ebrahimimarzieh overcomingtheucbhscsderivednkcellsdysfunctionthroughharnessingrasmapkigf1randtgfbsignalingpathways